Solid Tumours
Conditions
Keywords
VEGF, Pazopanib, Sarcoma, GW786034, Refractory Solid Tumors
Brief summary
The study design was an open-label Phase II pediatric clinical study. The purpose of Study X2203 was to identify any efficacy signal in subjects with the disease subtypes under study, when treated with pazopanib monotherapy. Furthermore, it was to define the toxicities of pazopanib in children, as well as examine biological markers, e.g. cytokines and angiogenic factors, that could help further characterize any response of pazopanib in children. Pazopanib was administered as monotherapy in tablet and powder suspension formulations at daily doses of 450 mg/m2/dose or 225 mg/m2/dose, respectively. The first 6 enrolled subjects receiving oral suspension formulation were assessed for tolerability and extended PK sampling; and, only if pazopanib was tolerated, subsequent subjects were enrolled at the same starting dose with the suspension. Dose escalation was not permitted. For the tablet, a dosing nomogram was used based on the subject's BSA. Dose reduction was dependent upon the toxicity of pazopanib and disease status of the infants, toddlers, children, adolescents, and young adults. Subjects could be as young as 1 year-old infants to screen for enrollment. Subjects were assessed for initial response after 8 weeks of treatment prior to Cycle 3. A cycle was defined as 28 days of pazopanib treatment with no rest period between cycles. Treatment was administered continuously once daily. Treatment was to be discontinued if there was evidence of disease progression, unacceptable treatment-related toxicity, pregnancy. Histological classification was an important diagnostic inclusion in these subjects with a wide variety of refractory solid tumors, i.e. 7 different tumor types and each being a cohort.
Detailed description
The study design included a hierarchical 2-stage tumor response assessment with each cohort independent from one other. First, an initial 10 subjects were enrolled into each cohort. In the event of ≥ 1 response in any of these initial subjects, an additional 10 subjects may be enrolled in that cohort to proceed. In the event of ≥ 3 responses, the agent was considered effective. However after end of-stage 1, study enrollment stopped due to insufficient antitumor activity. Subjects who discontinued study treatment were followed for survival status. The study was to continue accruing data and thus, remained open for approximately 1 year from Last Subject Last Visit (LSLV).
Interventions
DRUGPazopanib
Pazopanib was supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension was a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
Sponsors
Children's Oncology Group
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study design included a hierarchical 2-stage tumor response assessment with each cohort independent from one other. * Cohort 1: rhabdomyosarcoma (RMS) * Cohort 2: non-rhabdomyosarcomatous soft tissue sarcoma (NRSTS) * Cohort 3: Ewing sarcoma/pPNET * Cohort 4: osteosarcoma * Cohort 5: measurable neuroblastoma (mNeuroblastoma) * Cohort 6: evaluable neuroblastoma (eNeuroblastma) * Cohort 7: hepatoblastoma
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Subjects must be at least 1 and less than or equal to 18 years of age at the time of study entry. * Patients must have had histologic verification of one of the malignancies listed below at original diagnosis or at relapse - a) Rhabdomyosarcoma, b) Non-rhabdomyosarcomatous Soft Tissue Sarcoma (including desmoplastic small round cell tumor), c) Ewing Sarcoma / Peripheral Primitive Neuroectodermal Tumor (PNET), d) Osteosarcoma, e) Neuroblastoma (Measurable), f) Neuroblastoma (Evaluable), g) Hepatoblastoma. * Patient must have disease that has either relapsed or is refractory to prior therap * Patients who will be receiving the tablet formulation must have a body surface area (BSA) \>= 0.84 m\^2 (square meter) at baseline. * Patients must have radiographically measurable disease (with the exception of neuroblastoma), Measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm). * Patients with neuroblastoma who do not have measurable disease but have iodine-131 - meta-iodobenzylguanidine positive (MIBG+) evaluable disease are eligible. * Patients must have a Lansky or Karnofsky performance status score of \>= 50, corresponding to Eastern Cooperative Oncology Group (ECOG) categories 0, 1 or 2. Use Karnofsky for subjects \>= 16 years of age and Lansky for subjects \<= 16 years of age. * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. * Patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea). * At least 7 days must have elapsed since the completion of therapy with a growth factor that supports platelet or white cell number or function. At least 14 days must have elapsed after receiving peg-filgrastim. * At least 7 days must have elapsed since the completion of therapy with a biologic agent. For biologic agents that have known adverse events occurring beyond 7 days after administration, the period prior to enrollment must be extended beyond the time during which adverse events are known to occur. * Subjects may have received bevacizumab, VEGF-Trap, or other VEGF blocking tyrosine kinase inhibitors, provided that they did not progress while receiving one of these agents. Subjects may not have previously received pazopanib. * At least 21 days must have elapsed since the completion of the last dose of VEGF-Trap, and at least 7 days since a VEGF blocking tyrosine kinase inhibitor. Subjects must have recovered from any VEGF blocking drug-related toxicity (e.g., proteinuria). * \> = 21 days must have elapsed from infusion of last dose of antibody and toxicity related to prior antibody therapy must have recovered to Grade \<= 1. * Radiotherapy: \>=2 weeks must have elapsed since local palliative radiotherapy (XRT) (small port); \>=3 months must have elapsed if prior Traumatic Brain Injury (TBI), craniospinal XRT or if \>=50% radiation of pelvis; \>=6 weeks must have elapsed if other substantial bone marrow irradiation was given. * No evidence of active graft versus host disease and \>=2 months must have elapsed since transplant or rescue * Adequate Bone Marrow Function defined as peripheral absolute neutrophil count (ANC) \>=1000/ microlitre (µL), platelet count \>= 75,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment); and hemoglobin \>= 8.0 grams (g)/decilitre (dL), may receive red blood cell (RBC) transfusions. Subjects with bone marrow involvement will be eligible for study (provided they meet the criteria) but will not be evaluable for hematologic toxicity. * Adequate Renal and Metabolic Function defined as creatinine clearance or radioisotope Glomerular filtration rate (GFR) \>= 70 millilitre (mL)/ (min)/1.73 meter (m)\^2 or A serum creatinine based on age/gender as follows, age 1 to \< 2 years (male-0.6 milligrams (mg)/dL, female-0.6 mg/dL), age 2 to \< 6 years (male-0.8 mg/dL, female-0.8 mg/dL), age 6 to \< 10 years (male-1 mg/dL, female-1 mg/dL), age 10 to \< 13 years (male-1.2 mg/dL, female-1.2 mg/dL), age 13 to \< 16 years (male-1.5 mg/dL, female-1.4 mg/dL), age \>= 16 years (male-1.7 mg/dL, female-1.4 mg/dL), urine creatinine ratio of \<1 or a urinalysis that is negative for protein; or, 24-hour urine protein level \< 1000 mg/dL, adequate thyroid function ,no more than Grade 1 abnormalities of potassium, calcium (confirmed by ionized calcium), magnesium and phosphorous. * Adequate Liver Function defined as total bilirubin \<=1.5 x upper limit of normal (ULN) for age, serum glutamic-pyruvic transaminase (SGPT) Alanine transaminase (ALT) \<=2.5 x ULN (for the purpose of this study, the ULN for SGPT is 45 U/L), Serum albumin \>=2 g/dL. Must not have active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator assessment). NOTE: Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice, or cirrhosis. No known positivity of hepatitis B surface antigen (HBsAg), or of positive hepatitis C antibody. * Adequate Cardiac Function defined as shortening fraction of \>=27% by echocardiogram (while not receiving medications for cardiac function), or ejection fraction of \>= 50% by gated radionuclide study (while not receiving medications for cardiac function), the corrected QTc interval by Bazett's formula (QTcB) \<450 milliseconds (msec), and must not have a history of myocardial infarction, severe or unstable angina, peripheral vascular disease or familial QTc prolongation. * Adequate Blood Pressure Control defined as a blood pressure (BP) \<= the 95th percentile for age, height, and gender measured, subjects on stable doses of no more than one anti-hypertensive medication, with a baseline BP \<= 95th percentile for age, height and gender, will be eligible. * Central Nervous System (CNS) Function defined as subjects with a known history of seizures must have well-controlled seizures and may not be receiving enzyme-inducing anti-convulsants, CNS toxicity \<= Grade 2. * Adequate Coagulation defined as prothrombin time (PT) and partial thromboplastin time (PTT) \<= 1.2 x upper limit of normal and an international normalized ratio (INR) \<= 1.2. Key
Exclusion criteria
* Pregnant or breast-feeding women are not eligible for this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Negative pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method beginning at the signing of the informed consent until at least 2 weeks after the last dose of the study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate. Study drug may also potentially be secreted in milk and therefore breastfeeding women are excluded. Males (including those who have had vasectomies) with partners who can become pregnant will need to use birth control while on this study, as will their partner. Men are advised to use condoms during sexual intercourse while on study drug and continue to use adequate contraception for at least 2 weeks after the last dose of protocol therapy. * Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible. * Patients who are currently receiving another investigational drug are not eligible. * Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible. * Patients who are currently receiving more than one anti-hypertensive medication (Grade 3) or whose blood pressure is not well controlled are not eligible for study enrollment. * Patients must not be on therapeutic anticoagulation (Warfarin \[coumadin\] and/or low molecular weight heparin are prohibited). Prophylactic anticoagulation (i.e. intraluminal heparin) of venous or arterial access devices is allowed. * Patients receiving drugs with a known risk of torsades de pointes are not eligible. * Patients who require thyroid replacement therapy are not eligible if they have not been receiving a stable replacement dose for at least 4 weeks prior to study enrollment. * Patients who are unable to swallow tablets or liquid are not eligible. * Patients who have an uncontrolled infection are not eligible. * Patients will be excluded if any of the following are present, evidence of active bleeding, intratumoral hemorrhage, or bleeding diathesis; History (within 6 months prior to study enrollment) of arterial thromboembolic events, including transient ischemic attack (TIA) or cerebrovascular accident (CVA); history (within 6 months prior to study enrollment) of pulmonary embolism, deep venous thrombosis (DVT), or other venous thromboembolic event; history of clinically significant bleeding within 6 weeks prior to study enrollment. * Patients with known involvement of the CNS by malignancy will be excluded. * Patients who have had or are planning to have the following invasive procedures will be excluded- Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy (Subcutaneous port placement or central line placement is not considered major surgery but must be placed greater than 48 hours from planned Day 1 of therapy); Core biopsy within 7 days prior to Day 1 therapy; Fine needle aspirate or central line placement within 48 hours prior to Day 1therapy. * Patients with serious or non-healing wound, ulcer, or bone fracture. * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of study enrollment. * Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET) | From date of first dose of study treatment up to 55 months | ORR was defined as the percentage of participants achieving either a Complete Response (CR) or partial Response (PR) based on the Investigator review. The responses were assessed by CT or MRI based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST1.1). CR, disappearance of all target and non-target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion. Confirmation was based on the disease assessment at 1 cycle or at the next scheduled visit after the initial response. Only descriptive analysis performed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) as Assessed by the Investigator by Cohort | From date of first dose of study treatment up to 59 months | PFS was defined as the interval between the date of first dose of study medication and the earliest date of disease progression or death due to any cause. Disease progression was based on radiographic evidence, and assessments made by the investigator. According to RECIST1.1, disease progression was defined as at least a 20% increase in the sum of the disease measurements for measurable lesions, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions. For participants who did not progress or die, PFS was censored at the date of last adequate assessment or date of last adequate assessment prior to initiation of new anti-cancer therapy. Only descriptive analysis performed. |
| Time to Progression (TTP) by Cohort | From date of first dose of study treatment up to 59 months | The TTP was defined as the interval between the date of first dose of protocol therapy and the earliest date of disease progression or death due to disease under study. Subjects were considered to have progressive disease if they had documented progression based on radiologic assessment as determined by investigator review. According to RECIST1.1, disease progression was defined as at least a 20% increase in the sum of the disease measurements for measurable lesions, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions. Only descriptive analysis performed. |
| Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort | From date of first dose of study treatment up to 55 months | CBR was defined as the percentage of participants achieving either a confirmed complete response (CR) or confirmed partial response (PR) or Stable Disease (SD) for at least two protocol scheduled disease assessments based on RECIST1.1. CR, disappearance of all target and non-target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Only descriptive analysis performed. |
| Duration of Response (DOR) by Cohort | From date of first dose of study treatment up to 59 months | DoR was defined as the time from initial response to the first documented disease progression or death due to any cause, and was determined only for those participants from the mITT population with a confirmed response (CR or PR). Only descriptive analysis performed. |
| Overall Survival (OS) by Cohort | From date of first dose of study treatment up to 61 months | OS was defined as the time from the first dose of the study medication until death due to any cause. Only descriptive analysis performed. |
| Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose) | AUC0-8h and AUClast were calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. |
| Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Secondary Interest (Osteosarcoma, mNeuroblastoma, eNeuroblastoma or Hepatoblastoma) | From date of first dose of study treatment up to 55 months | ORR was defined as the percentage of participants achieving either a Complete Response (CR) or partial Response (PR) based on the Investigator review. For solid tumors with measurable diseases, such as osteosarcoma, the responses was based on RECIST1.1. CR, disappearance of all target and non target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion. For neuroblastoma with bone marrow response, morphology was determined by hematoxylin and eosin staining of the marrow and aspirates. For neuroblastoma MIBG+ only, the responses was assessed using Curie scale for lesion scoring; For hepatoblastoma, assessment may have included the serum AFP response, in addition to the RECIST1.1 methodology. Only descriptive analysis performed. |
| Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose) | Tmax was calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. |
| Pazopanib Steady-state Trough (Ctrough) Levels for Participants With Drug-related Grade 2 and Above Hypertension | From date of first dose of study treatment up to 61 months | The relationship between toxicity (including hypertension) and pharmacokinetic parameters (pazopanib trough concentration) was analyzed. Only descriptive analysis performed. |
| Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | predose Cycle 1 Day 1, Cycle 2 Day 1 | The frequency of genetic alterations observed in participants was presented by high and low baseline plasma levels for Vascular endothelial growth factor A (VEGF-A) and Vascular endothelial growth factor receptor 1 (VEGFR-1) biomarkers. The VEGFA and VEGFR1 levels above the median were classified as high and participants with median levels or below were classified as low. Only descriptive analysis performed for participants presenting with a genetic alteration. |
| Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | predose Cycle 1 Day 1, Cycle 2 Day 1 | The following biomarker parameters were analyzed: proto-oncogene c-KIT (c-KIT), Fibroblast growth factor (FGF), Placental growth factor PGF), Angiopoietin-1 receptor (TIE2), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Vascular endothelial growth factor receptor 1 (VEGFR-1) and Vascular endothelial growth factor receptor 2 (VEGFR-2)). Only descriptive analysis performed. |
| Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | predose Cycle 1 Day 1, Cycle 2 Day 1 | Participants with steady state trough concentration median levels for the following biomarker parameters (proto-oncogene c-KIT (c-KIT), Fibroblast growth factor (FGF), Placental growth factor PGF), Angiopoietin-1 receptor (TIE2), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Vascular endothelial growth factor receptor 1 (VEGFR-1) and Vascular endothelial growth factor receptor 2 (VEGFR-2)) above the median levels were classified as high or below median levels were classified as low. Only descriptive analysis performed. |
| Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose) | Cmax was calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed. |
Countries
Canada, Czechia, France, Hungary, Slovakia, Spain, United States
Participant flow
Recruitment details
This study was conducted at 30 centers in 7 countries: Canada (2), Czech Republic (1), France (1), Hungary (1), Slovakia (1), Spain (1) and USA (23).
Pre-assignment details
154 patients were planned to be enrolled in the study. A total of 57 patients were randomized and analyzed: cohort 1 (12), cohort 2 (11), cohort 3 (10), cohort 4 (10), cohort 5 (4), cohort 6 (4) and cohort 7 (6).
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles. | 12 |
| Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles. | 11 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles. | 10 |
| Cohort 4 (Osteosarcoma) Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles. | 10 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles. | 4 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles. | 4 |
| Cohort 7 (Hepatoblastoma) Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\^2/dose or as a powder in suspension at a dose of 225 mg/m\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\^2/dose was not tolerated (\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\^2/dose. A cycle was defined as 28 days with no rest periods between cycles. | 6 |
| Total | 57 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| Overall Study | Disease Progression | 12 | 7 | 7 | 8 | 4 | 3 | 5 |
| Overall Study | Physician Decision | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Cohort 1: Rhabdomyosarcoma (RMS) | Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS) | Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Cohort 4 (Osteosarcoma) | Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Cohort 7 (Hepatoblastoma) | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 9.8 Years STANDARD_DEVIATION 3.82 | 15.7 Years STANDARD_DEVIATION 1.19 | 12.6 Years STANDARD_DEVIATION 4.67 | 14.1 Years STANDARD_DEVIATION 3.57 | 9.8 Years STANDARD_DEVIATION 5.91 | 13.0 Years STANDARD_DEVIATION 4.24 | 5.3 Years STANDARD_DEVIATION 4.8 | 11.9 Years STANDARD_DEVIATION 4.84 |
| Race/Ethnicity, Customized African American/African heritage | 1 Participants | 2 Participants | 3 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 10 Participants |
| Race/Ethnicity, Customized American Indian/Alaskan native | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Central/South Asian heritage | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Japanese heritage | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Missing | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 4 Participants |
| Race/Ethnicity, Customized Native Hawaiian/other Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Southeast Asian heritage | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized White Arabic/White North African heritage | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized White/Caucasian/European heritage | 9 Participants | 7 Participants | 6 Participants | 7 Participants | 3 Participants | 3 Participants | 1 Participants | 36 Participants |
| Sex: Female, Male Female | 5 Participants | 4 Participants | 3 Participants | 1 Participants | 3 Participants | 3 Participants | 5 Participants | 24 Participants |
| Sex: Female, Male Male | 7 Participants | 7 Participants | 7 Participants | 9 Participants | 1 Participants | 1 Participants | 1 Participants | 33 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 12 | 0 / 11 | 1 / 10 | 3 / 10 | 0 / 4 | 1 / 4 | 1 / 6 | 9 / 57 |
| other Total, other adverse events | 12 / 12 | 11 / 11 | 10 / 10 | 10 / 10 | 4 / 4 | 4 / 4 | 6 / 6 | 57 / 57 |
| serious Total, serious adverse events | 2 / 12 | 5 / 11 | 3 / 10 | 3 / 10 | 0 / 4 | 1 / 4 | 3 / 6 | 17 / 57 |
Outcome results
Primary
Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET)
ORR was defined as the percentage of participants achieving either a Complete Response (CR) or partial Response (PR) based on the Investigator review. The responses were assessed by CT or MRI based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST1.1). CR, disappearance of all target and non-target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion. Confirmation was based on the disease assessment at 1 cycle or at the next scheduled visit after the initial response. Only descriptive analysis performed.
Time frame: From date of first dose of study treatment up to 55 months
Population: mITT Set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET) | 8.3 Percentage of Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET) | 0.0 Percentage of Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET) | 0.0 Percentage of Participants |
Secondary
Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort
AUC0-8h and AUClast were calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed.
Time frame: Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose)
Population: PKES set
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUC0-8h (C1D1) | 195 ng*hr/mL | Geometric Coefficient of Variation 19 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUC0-8h (C1D15) | 388 ng*hr/mL | Geometric Coefficient of Variation 55.9 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUClast (C1D1) | 194 ng*hr/mL | Geometric Coefficient of Variation 19.6 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUClast (C1D15) | 966 ng*hr/mL | Geometric Coefficient of Variation 58.1 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUClast (C1D15) | 633 ng*hr/mL | Geometric Coefficient of Variation 35.4 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUClast (C1D1) | 189 ng*hr/mL | Geometric Coefficient of Variation 65.8 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUC0-8h (C1D15) | 266 ng*hr/mL | Geometric Coefficient of Variation 36.1 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUC0-8h (C1D1) | 214 ng*hr/mL | Geometric Coefficient of Variation 93.2 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUClast (C1D15) | 1230 ng*hr/mL | — |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUC0-8h (C1D15) | 475 ng*hr/mL | — |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUClast (C1D15) | 1490 ng*hr/mL | — |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUC0-8h (C1D15) | 566 ng*hr/mL | — |
| Cohort 7 (Hepatoblastoma) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUClast (C1D1) | 135 ng*hr/mL | Geometric Coefficient of Variation 60.2 |
| Cohort 7 (Hepatoblastoma) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUClast (C1D15) | 607 ng*hr/mL | Geometric Coefficient of Variation 85 |
| Cohort 7 (Hepatoblastoma) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUC0-8h (C1D15) | 229 ng*hr/mL | Geometric Coefficient of Variation 89.5 |
| Cohort 7 (Hepatoblastoma) | Area Under the Plasma Concentration-time Curve Calculated From Time 0 to 8 h Postdose (AUC0-8h) and Calculated to the Last Quantifiable Concentration Point (AUClast) of Pazopanib by Cohort | AUC0-8h (C1D1) | 135 ng*hr/mL | Geometric Coefficient of Variation 60.2 |
Secondary
Duration of Response (DOR) by Cohort
DoR was defined as the time from initial response to the first documented disease progression or death due to any cause, and was determined only for those participants from the mITT population with a confirmed response (CR or PR). Only descriptive analysis performed.
Time frame: From date of first dose of study treatment up to 59 months
Population: mITT Set
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Duration of Response (DOR) by Cohort | NA Months |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Duration of Response (DOR) by Cohort | NA Months |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Duration of Response (DOR) by Cohort | NA Months |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Duration of Response (DOR) by Cohort | NA Months |
| Cohort 7 (Hepatoblastoma) | Duration of Response (DOR) by Cohort | NA Months |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Duration of Response (DOR) by Cohort | NA Months |
| Cohort 7 (Hepatoblastoma) | Duration of Response (DOR) by Cohort | NA Months |
Secondary
Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1
The frequency of genetic alterations observed in participants was presented by high and low baseline plasma levels for Vascular endothelial growth factor A (VEGF-A) and Vascular endothelial growth factor receptor 1 (VEGFR-1) biomarkers. The VEGFA and VEGFR1 levels above the median were classified as high and participants with median levels or below were classified as low. Only descriptive analysis performed for participants presenting with a genetic alteration.
Time frame: predose Cycle 1 Day 1, Cycle 2 Day 1
Population: Biomarker set. Only participants with single nucleotide variant (SNV) were included in the analysis. The FLT1 gene was found to have a single SNV in one evaluable neuroblastoma participant.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | VHL | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KRAS | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | HIF1A | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KRAS | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | VHL | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PLCG1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | VHL | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PIK3R1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KDR | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KDR | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | FLT1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PIK3R1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | FLT1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | HIF1A | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | HIF1A | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PIK3R1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KDR | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | MAPK1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KRAS | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | FLT1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PLCG1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PLCG1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KRAS | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | MAPK1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PIK3R1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PLCG1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | MAPK1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | VHL | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | HIF1A | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | MAPK1 | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KDR | 0 Participants |
| Cohort 1: Rhabdomyosarcoma (RMS) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | FLT1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KRAS | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | HIF1A | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KDR | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PIK3R1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | MAPK1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | HIF1A | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | MAPK1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KRAS | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | HIF1A | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KDR | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | VHL | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | FLT1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PLCG1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | VHL | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | FLT1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | FLT1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PIK3R1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KDR | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | VHL | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PIK3R1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | HIF1A | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KRAS | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PIK3R1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | FLT1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PLCG1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PLCG1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | MAPK1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PLCG1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KDR | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | VHL | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | MAPK1 | 0 Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KRAS | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KRAS | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | HIF1A | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PLCG1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | VHL | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PLCG1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | MAPK1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PIK3R1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | MAPK1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PIK3R1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PLCG1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | FLT1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | VHL | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | VHL | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | MAPK1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KRAS | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | HIF1A | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | VHL | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | FLT1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | MAPK1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KRAS | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KRAS | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KDR | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KDR | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KDR | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PLCG1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | HIF1A | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | HIF1A | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KDR | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PIK3R1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | FLT1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | FLT1 | 0 Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PIK3R1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KRAS | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KRAS | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KRAS | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PIK3R1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KDR | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | HIF1A | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KDR | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | FLT1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | VHL | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | FLT1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | MAPK1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | VHL | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PLCG1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KRAS | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PIK3R1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | MAPK1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PLCG1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KDR | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | VHL | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | MAPK1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | FLT1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KDR | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | HIF1A | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | HIF1A | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PIK3R1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PIK3R1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | MAPK1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PLCG1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PLCG1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | FLT1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | VHL | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | HIF1A | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KDR | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | VHL | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PIK3R1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | MAPK1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | MAPK1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PLCG1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | MAPK1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PIK3R1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KRAS | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | HIF1A | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KRAS | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PLCG1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | HIF1A | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PLCG1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PIK3R1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KDR | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | FLT1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | VHL | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PLCG1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | MAPK1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | HIF1A | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | VHL | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | FLT1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KDR | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | FLT1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PIK3R1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KRAS | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | HIF1A | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KDR | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KRAS | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | VHL | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | FLT1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PLCG1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | MAPK1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KRAS | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PIK3R1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | MAPK1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | VHL | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | FLT1 | 1 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | VHL | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | FLT1 | 1 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KDR | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | HIF1A | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KRAS | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PIK3R1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PLCG1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | VHL | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | FLT1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KDR | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | HIF1A | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PIK3R1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | MAPK1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PLCG1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | VHL | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | FLT1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KDR | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | HIF1A | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KRAS | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KDR | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | HIF1A | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KRAS | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PIK3R1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | MAPK1 | 0 Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PLCG1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KDR | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | HIF1A | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KRAS | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | VHL | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PLCG1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | MAPK1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | PIK3R1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KRAS | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | VHL | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PIK3R1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | HIF1A | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | KDR | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | FLT1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA High | VHL | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PLCG1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PLCG1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | MAPK1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | MAPK1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | PIK3R1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KRAS | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | HIF1A | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | KDR | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | FLT1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | PLCG1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | FLT1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFA Low | VHL | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | MAPK1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | KDR | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 High | FLT1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | PIK3R1 | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | KRAS | 0 Participants |
| Cohort 7 (Hepatoblastoma) | Number of Participants With Genetic Alterations by Low and High Values of VEGFA and VEGFR1 | VEGFR1 Low | HIF1A | 0 Participants |
Secondary
Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort
Cmax was calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed.
Time frame: Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose)
Population: PKES set
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Cmax (C1D1) | 34.7 ng/mL | Geometric Coefficient of Variation 14.7 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Cmax (C1D15) | 56.7 ng/mL | Geometric Coefficient of Variation 53.3 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Cmax (C1D15) | 42.0 ng/mL | Geometric Coefficient of Variation 42.3 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Cmax (C1D1) | 35.6 ng/mL | Geometric Coefficient of Variation 75.9 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Cmax (C1D1) | 0.0 ng/mL | — |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Cmax (C1D15) | 69.6 ng/mL | — |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Cmax (C1D15) | 80.2 ng/mL | — |
| Cohort 7 (Hepatoblastoma) | Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Cmax (C1D15) | 33.4 ng/mL | Geometric Coefficient of Variation 95.9 |
| Cohort 7 (Hepatoblastoma) | Observed Maximum Plasma Concentration (Cmax) of Pazopanib by Cohort | Cmax (C1D1) | 22.4 ng/mL | Geometric Coefficient of Variation 73.7 |
Secondary
Overall Survival (OS) by Cohort
OS was defined as the time from the first dose of the study medication until death due to any cause. Only descriptive analysis performed.
Time frame: From date of first dose of study treatment up to 61 months
Population: mITT Set
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Overall Survival (OS) by Cohort | 5.6 Months |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Overall Survival (OS) by Cohort | 14.6 Months |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Overall Survival (OS) by Cohort | NA Months |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Overall Survival (OS) by Cohort | 5.5 Months |
| Cohort 7 (Hepatoblastoma) | Overall Survival (OS) by Cohort | NA Months |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Overall Survival (OS) by Cohort | 5.4 Months |
| Cohort 7 (Hepatoblastoma) | Overall Survival (OS) by Cohort | 5.7 Months |
Secondary
Pazopanib Steady-state Trough (Ctrough) Levels for Participants With Drug-related Grade 2 and Above Hypertension
The relationship between toxicity (including hypertension) and pharmacokinetic parameters (pazopanib trough concentration) was analyzed. Only descriptive analysis performed.
Time frame: From date of first dose of study treatment up to 61 months
Population: PK set. Only participants with a drug-related grade 2 and above hypertension event included in the analysis
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Pazopanib Steady-state Trough (Ctrough) Levels for Participants With Drug-related Grade 2 and Above Hypertension | 97.1 ng/mL | — |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Pazopanib Steady-state Trough (Ctrough) Levels for Participants With Drug-related Grade 2 and Above Hypertension | 35.7 ng/mL | Geometric Coefficient of Variation 22.6 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Pazopanib Steady-state Trough (Ctrough) Levels for Participants With Drug-related Grade 2 and Above Hypertension | 35.7 ng/mL | — |
| Cohort 7 (Hepatoblastoma) | Pazopanib Steady-state Trough (Ctrough) Levels for Participants With Drug-related Grade 2 and Above Hypertension | 38.0 ng/mL | Geometric Coefficient of Variation 20.8 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Pazopanib Steady-state Trough (Ctrough) Levels for Participants With Drug-related Grade 2 and Above Hypertension | 63.7 ng/mL | — |
Secondary
Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort
CBR was defined as the percentage of participants achieving either a confirmed complete response (CR) or confirmed partial response (PR) or Stable Disease (SD) for at least two protocol scheduled disease assessments based on RECIST1.1. CR, disappearance of all target and non-target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Only descriptive analysis performed.
Time frame: From date of first dose of study treatment up to 55 months
Population: mITT set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort | 8.3 Percentage of Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort | 27.3 Percentage of Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort | 20.0 Percentage of Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort | 20.0 Percentage of Participants |
| Cohort 7 (Hepatoblastoma) | Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort | 50.0 Percentage of Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort | 25.0 Percentage of Participants |
| Cohort 7 (Hepatoblastoma) | Percentage of Participants Achieving Clinical Benefit Rate (CBR) by Cohort | 0.0 Percentage of Participants |
Secondary
Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Secondary Interest (Osteosarcoma, mNeuroblastoma, eNeuroblastoma or Hepatoblastoma)
ORR was defined as the percentage of participants achieving either a Complete Response (CR) or partial Response (PR) based on the Investigator review. For solid tumors with measurable diseases, such as osteosarcoma, the responses was based on RECIST1.1. CR, disappearance of all target and non target lesions; PR, at least a 30% decrease in the disease measurement, taking as reference the disease measurement done to confirm measurable disease at study enrollment, also no new lesion or progression of any non-target measurable lesion. For neuroblastoma with bone marrow response, morphology was determined by hematoxylin and eosin staining of the marrow and aspirates. For neuroblastoma MIBG+ only, the responses was assessed using Curie scale for lesion scoring; For hepatoblastoma, assessment may have included the serum AFP response, in addition to the RECIST1.1 methodology. Only descriptive analysis performed.
Time frame: From date of first dose of study treatment up to 55 months
Population: mITT set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Secondary Interest (Osteosarcoma, mNeuroblastoma, eNeuroblastoma or Hepatoblastoma) | 0.0 Percentage of Participants |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Secondary Interest (Osteosarcoma, mNeuroblastoma, eNeuroblastoma or Hepatoblastoma) | 0.0 Percentage of Participants |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Secondary Interest (Osteosarcoma, mNeuroblastoma, eNeuroblastoma or Hepatoblastoma) | 0.0 Percentage of Participants |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Secondary Interest (Osteosarcoma, mNeuroblastoma, eNeuroblastoma or Hepatoblastoma) | 0.0 Percentage of Participants |
Secondary
Progression Free Survival (PFS) as Assessed by the Investigator by Cohort
PFS was defined as the interval between the date of first dose of study medication and the earliest date of disease progression or death due to any cause. Disease progression was based on radiographic evidence, and assessments made by the investigator. According to RECIST1.1, disease progression was defined as at least a 20% increase in the sum of the disease measurements for measurable lesions, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions. For participants who did not progress or die, PFS was censored at the date of last adequate assessment or date of last adequate assessment prior to initiation of new anti-cancer therapy. Only descriptive analysis performed.
Time frame: From date of first dose of study treatment up to 59 months
Population: mITT set
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Progression Free Survival (PFS) as Assessed by the Investigator by Cohort | 1.8 Months |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Progression Free Survival (PFS) as Assessed by the Investigator by Cohort | 1.8 Months |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Progression Free Survival (PFS) as Assessed by the Investigator by Cohort | 2.3 Months |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Progression Free Survival (PFS) as Assessed by the Investigator by Cohort | 1.9 Months |
| Cohort 7 (Hepatoblastoma) | Progression Free Survival (PFS) as Assessed by the Investigator by Cohort | 4.9 Months |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Progression Free Survival (PFS) as Assessed by the Investigator by Cohort | 5.4 Months |
| Cohort 7 (Hepatoblastoma) | Progression Free Survival (PFS) as Assessed by the Investigator by Cohort | 1.8 Months |
Secondary
Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort
Participants with steady state trough concentration median levels for the following biomarker parameters (proto-oncogene c-KIT (c-KIT), Fibroblast growth factor (FGF), Placental growth factor PGF), Angiopoietin-1 receptor (TIE2), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Vascular endothelial growth factor receptor 1 (VEGFR-1) and Vascular endothelial growth factor receptor 2 (VEGFR-2)) above the median levels were classified as high or below median levels were classified as low. Only descriptive analysis performed.
Time frame: predose Cycle 1 Day 1, Cycle 2 Day 1
Population: Biomarker set. Only patient with steady state trough plasma Pazopanib concentration included in the analysis.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-A low trough concentration | 2436.6 picogram/milliliter (pg/mL) |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | TIE2 low trough concentration | 1212.4 picogram/milliliter (pg/mL) |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-2 low trough concentration | -12130.8 picogram/milliliter (pg/mL) |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-1 low trough concentration | 484.1 picogram/milliliter (pg/mL) |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | c-KIT low trough concentration | -13480.5 picogram/milliliter (pg/mL) |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-D low trough concentration | 423.2 picogram/milliliter (pg/mL) |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-A low trough concentration | 18.5 picogram/milliliter (pg/mL) |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | PGF low trough concentration | 5.6 picogram/milliliter (pg/mL) |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-2 low trough concentration | -7795.4 picogram/milliliter (pg/mL) |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-1 low trough concentration | -67.2 picogram/milliliter (pg/mL) |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-D low trough concentration | 44.1 picogram/milliliter (pg/mL) |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | TIE2 low trough concentration | -1514.9 picogram/milliliter (pg/mL) |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | c-KIT low trough concentration | -44973.7 picogram/milliliter (pg/mL) |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-A high trough concentration | 358.8 picogram/milliliter (pg/mL) |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | c-KIT high trough concentration | -76081.1 picogram/milliliter (pg/mL) |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | PGF high trough concentration | 78.3 picogram/milliliter (pg/mL) |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-1 high trough concentration | -217.5 picogram/milliliter (pg/mL) |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-D high trough concentration | 88.0 picogram/milliliter (pg/mL) |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-2 high trough concentration | -2620.0 picogram/milliliter (pg/mL) |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | TIE2 high trough concentration | 2553.0 picogram/milliliter (pg/mL) |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | FGF high trough concentration | -7.0 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-1 high trough concentration | 955.6 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | c-KIT high trough concentration | -40512.6 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | c-KIT low trough concentration | -48764.1 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | PGF high trough concentration | 15.6 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | PGF low trough concentration | 28.3 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | TIE2 high trough concentration | -509.4 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | TIE2 low trough concentration | -918.4 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-A high trough concentration | 34.3 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-A low trough concentration | 52.3 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-D high trough concentration | 139.7 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-D low trough concentration | 153.5 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-1 low trough concentration | -7.7 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-2 high trough concentration | -16136.9 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-2 low trough concentration | -8588.1 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-A high trough concentration | -73.3 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-1 high trough concentration | -49.7 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | TIE2 low trough concentration | -473.0 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | TIE2 high trough concentration | -2708.2 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | c-KIT high trough concentration | -51199.4 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-1 low trough concentration | -741.3 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | PGF high trough concentration | 45.4 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-2 low trough concentration | -10529.6 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGFR-2 high trough concentration | -16838.7 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-D high trough concentration | 187.5 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | c-KIT low trough concentration | -35678.6 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-D low trough concentration | 90.8 picogram/milliliter (pg/mL) |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Change From Baseline Levels of Plasma Biomarkers by High and Low Pazopanib Steady State Trough Concentration and Cohort | VEGF-A low trough concentration | 39.7 picogram/milliliter (pg/mL) |
Secondary
Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort
The following biomarker parameters were analyzed: proto-oncogene c-KIT (c-KIT), Fibroblast growth factor (FGF), Placental growth factor PGF), Angiopoietin-1 receptor (TIE2), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Vascular endothelial growth factor receptor 1 (VEGFR-1) and Vascular endothelial growth factor receptor 2 (VEGFR-2)). Only descriptive analysis performed.
Time frame: predose Cycle 1 Day 1, Cycle 2 Day 1
Population: Biomarker set
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C2D1) | 54.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 259.4 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-C (C1D1) | 121.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 1.6 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C1D1) | 19.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 245.7 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | FGF (C2D1) | 15.1 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 68.9 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C1D1) | 31451.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 22.6 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C2D1) | 87.5 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 98.5 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C1D1) | 394.5 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 292.3 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C2D1) | 434.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 77.4 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C1D1) | 354.2 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 54.6 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C2D1) | 110154.0 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 14.1 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C1D1) | 139522.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 29.4 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-C (C2D1) | 105.9 picogram/milliliter (pg/mL) | — |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C2D1) | 123.3 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 140.6 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C1D1) | 63.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 133.8 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C2D1) | 8340.1 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 11.5 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C1D1) | 8086.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 26.5 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | FGF (C1D1) | 7.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 63.1 |
| Cohort 1: Rhabdomyosarcoma (RMS) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C2D1) | 25099.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 22.9 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C1D1) | 8.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 27.6 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C1D1) | 142526.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 24.3 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C2D1) | 99962.7 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 8.2 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | FGF (C1D1) | 6.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 71.1 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | FGF (C2D1) | 6.2 picogram/milliliter (pg/mL) | — |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C2D1) | 27.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 74.9 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C1D1) | 8180.0 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 25 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C2D1) | 7788.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 11.5 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C1D1) | 46.1 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 66.1 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C2D1) | 77.2 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 166.8 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-C (C1D1) | 152.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 84.7 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-C (C2D1) | 339.9 picogram/milliliter (pg/mL) | — |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C1D1) | 372.3 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 20.5 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C2D1) | 501.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 43 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C1D1) | 175.7 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 174.4 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C2D1) | 534.3 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 709.9 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C1D1) | 31745.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 20.6 |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C2D1) | 23059.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 21.6 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C1D1) | 135024.5 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 25.9 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | FGF (C1D1) | 8.3 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 59.1 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C1D1) | 33724.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 15.8 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C1D1) | 74.0 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 98 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C2D1) | 93.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 121.1 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C1D1) | 7280.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 15.6 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C2D1) | 448.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 16.9 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C1D1) | 9.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 36.9 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C2D1) | 23502.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 1 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C1D1) | 394.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 21.6 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C2D1) | 171.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 126 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C2D1) | 7650.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 22.7 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C2D1) | 94307.1 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 15.1 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C1D1) | 224.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 121.7 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C2D1) | 37.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 82.9 |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | FGF (C2D1) | 5.1 picogram/milliliter (pg/mL) | — |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C2D1) | 22154.3 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 15.1 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C1D1) | 375.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 43.9 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C2D1) | 63.2 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 113.8 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C1D1) | 10.5 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 37 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | FGF (C1D1) | 5.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 6 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C1D1) | 34993.1 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 17.6 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C2D1) | 7894.1 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 17.4 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C1D1) | 82.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 62 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C2D1) | 140.0 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 231.3 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C1D1) | 137317.7 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 23.9 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C2D1) | 99989.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 18.9 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C1D1) | 134.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 113.7 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C2D1) | 179.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 98.7 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C1D1) | 8574.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 7.7 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C2D1) | 551.7 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 14.4 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C2D1) | 219.3 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 40.4 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C1D1) | 7439.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 4.6 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C2D1) | 8026.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 28.2 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C2D1) | 121497.7 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 23 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C1D1) | 31682.1 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 12.1 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C1D1) | 48.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 39 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C2D1) | 30.3 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 300.5 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C1D1) | 645.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 108.7 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C2D1) | 501.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 50.1 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C1D1) | 142630.1 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 18 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C1D1) | 95.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 42.9 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C2D1) | 25385.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 42.9 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C2D1) | 69.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 4.9 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | FGF (C2D1) | 6.6 picogram/milliliter (pg/mL) | — |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C1D1) | 9.3 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 6.2 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C2D1) | 791.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 51.1 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C1D1) | 13.7 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 126.6 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C2D1) | 1057.5 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 750 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C1D1) | 39342.8 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 14.7 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C1D1) | 367.5 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 130.8 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C1D1) | 62.2 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 268.3 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C2D1) | 13621.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 68.5 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C2D1) | 76.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 14.6 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C2D1) | 6824.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 32 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | FGF (C1D1) | 13.5 picogram/milliliter (pg/mL) | — |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C2D1) | 71216.5 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 2 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C1D1) | 8179.2 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 30 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C1D1) | 351.7 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 12.1 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C1D1) | 113596.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 26.6 |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C2D1) | 225.2 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 840.1 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C2D1) | 400.4 picogram/milliliter (pg/mL) | — |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C2D1) | 8540.0 picogram/milliliter (pg/mL) | — |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C2D1) | 208.9 picogram/milliliter (pg/mL) | — |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C1D1) | 119921.9 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 30.6 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C2D1) | 39.4 picogram/milliliter (pg/mL) | — |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | PGF (C1D1) | 8.6 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 29.7 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-D (C1D1) | 370.0 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 75.9 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C1D1) | 173.4 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 109.6 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGF-A (C1D1) | 129.3 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 46.6 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | c-KIT (C2D1) | 154558.2 picogram/milliliter (pg/mL) | — |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C1D1) | 30780.5 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 6 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | TIE2 (C1D1) | 7842.2 picogram/milliliter (pg/mL) | Geometric Coefficient of Variation 18.3 |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-2 (C2D1) | 26266.9 picogram/milliliter (pg/mL) | — |
| Cohort 7 (Hepatoblastoma) | Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort | VEGFR-1 (C2D1) | 1811.6 picogram/milliliter (pg/mL) | — |
Secondary
Time to Progression (TTP) by Cohort
The TTP was defined as the interval between the date of first dose of protocol therapy and the earliest date of disease progression or death due to disease under study. Subjects were considered to have progressive disease if they had documented progression based on radiologic assessment as determined by investigator review. According to RECIST1.1, disease progression was defined as at least a 20% increase in the sum of the disease measurements for measurable lesions, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions. Only descriptive analysis performed.
Time frame: From date of first dose of study treatment up to 59 months
Population: mITT set
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Time to Progression (TTP) by Cohort | 1.8 Months |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Time to Progression (TTP) by Cohort | 1.8 Months |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Time to Progression (TTP) by Cohort | 2.3 Months |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Time to Progression (TTP) by Cohort | 1.9 Months |
| Cohort 7 (Hepatoblastoma) | Time to Progression (TTP) by Cohort | 4.9 Months |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Time to Progression (TTP) by Cohort | 14.9 Months |
| Cohort 7 (Hepatoblastoma) | Time to Progression (TTP) by Cohort | 1.8 Months |
Secondary
Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort
Tmax was calculated using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) and the LLOQ was 0.100 µg/mL. PK parameters were calculated from plasma concentration-time data using non-compartmental methods. Only descriptive analysis performed.
Time frame: Day 1 of Cycle 1 (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose); Cycle 1 Day 15 ± 1 day (0, 0.5, 1, 2, 4, 6 and 8 hours post-dose)
Population: PKES set
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Cohort 1: Rhabdomyosarcoma (RMS) | Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Tmax (C1D15) | 2.50 Hours |
| Cohort 1: Rhabdomyosarcoma (RMS) | Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Tmax (C1D1) | 1 Hours |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Tmax (C1D1) | 2.02 Hours |
| Cohort 3: Ewing Sarcoma/pPNET (Ewing) | Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Tmax (C1D15) | 1.00 Hours |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Tmax (C1D1) | 0.00 Hours |
| Cohort 5: Measurable Neuroblastoma (mNeuroblastoma) | Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Tmax (C1D15) | 3.47 Hours |
| Cohort 6: Evaluable Neuroblastoma (eNeuroblastma) | Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Tmax (C1D15) | 3.03 Hours |
| Cohort 7 (Hepatoblastoma) | Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Tmax (C1D15) | 3.00 Hours |
| Cohort 7 (Hepatoblastoma) | Time to Reach Peak or Maximum Concentration (Tmax) of Pazopanib by Cohort | Tmax (C1D1) | 2.00 Hours |